Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review

Although many strategies have been developed for non-small cell lung cancer (NSCLC), more secondary and further treatments are needed due to drug resistance or tumor recurrence. Apatinib is a novel oral antiangiogenic agent and in this study, we aim to investigate the clinical value of apatinib in h...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Dexiang, Dai, Ranran, Zhang, Qi, Fang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087811/
https://www.ncbi.nlm.nih.gov/pubmed/30108437
http://dx.doi.org/10.1016/j.sjbs.2017.12.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087811/
https://www.ncbi.nlm.nih.gov/pubmed/30108437
http://dx.doi.org/10.1016/j.sjbs.2017.12.011

Ejemplares similares